Health Canada Approves HPV Vaccine, Types 16 and 18
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Health Canada Approves HPV Vaccine, Types 16 and 18

NEW YORK -- February 9, 2010 -- Health Canada has approved a new adjuvanted (AS04) human papillomavirus (HPV) vaccine (types 16 and 18 [Cervarix]) to protect girls and women aged 10 to 25 years against cervical cancer and abnormal and precancerous cervical lesions.

“In Canada, more than 1 woman dies every day from cervical cancer, a disease that is largely preventable,” said Barbara Romanowski, MD, Division of Infectious Diseases, University of Alberta, Edmonton, Alberta. “Together with regular Pap tests, Cervarix reduces the risk of cervical cancer caused by HPV types 16 and 18, by 98%.”

The vaccine contains a unique adjuvant system, AS04, which has been added to improve the immune response by providing stronger and longer protection as compared with a traditional adjuvant.

A phase 3 trial, which included over 18,000 women, evaluated the efficacy of HPV types 16 and 18 as well as other cancer causing HPV types. In 1 analysis the vaccine demonstrated protection against HPV type 45 in addition to types 16 and 18. In another, the vaccine demonstrated protection against HPV type 31 in addition to types 16 and 18.

The vaccine was generally well tolerated. The most common local adverse reactions and general adverse events in >=20% of subjects were pain, redness, and swelling at the injection site; fatigue, headache, myalgia, gastrointestinal symptoms, and arthralgia.

SOURCE: GlaxoSmithKline

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities